AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 ...
PharmExec

Boehringer Ingelheim Acquires Exclusive License from Sitryx Therapeutics for Preclinical Small Molecule Program

Boehringer Ingelheim acquires an exclusive license for a preclinical oral immunology program from Sitryx in a deal worth over ...

Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership

PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients ...
Fierce Biotech

Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases

Boehringer Ingelheim has penned a $500 million deal with a British biotech for a preclinical program the German pharma hopes could offer a fresh oral treatment approach to a variety of autoimmune a | ...

Chemify and Sanacor Collaborate to Discover and Develop Small Molecule Therapies for Cardiometabolic Diseases

Partnership to use Chemify’s programmable chemistry technology and Sanacor’s translational biology expertise to accelerate small-molecule discovery addressing mitochondrial dysfunction GLASGOW, ...
News Medical

INTEGRA Biosciences’ pipettes help progress small molecule inhibitors from discovery to clinical trials

RAPT Therapeutics in San Francisco, USA, relies on INTEGRA Biosciences’ pipettes to seamlessly accelerate the development of its candidate small molecule inhibitors for the treatment of inflammatory ...
EurekAlert!

Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics

This new article publication from Acta Pharmaceutica Sinica B, discusses the identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics. There are only eight approved small ...

CVKD: Acquires 12-LOX Inhibitor for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires 12-LOX Inhibitor VLX-1005 for the Treatment of HIT In December 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced the ...